Expasy logo

UniProtKB/Swiss-Prot variant pages

Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot P37173: Variant p.Arg528His

TGF-beta receptor type-2
Gene: TGFBR2
Feedback?
Variant information Variant position: help 528 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Histidine (H) at position 528 (R528H, p.Arg528His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In LDS2. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 528 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 567 The length of the canonical sequence.
Location on the sequence: help QGIQMVCETLTECWDHDPEA R LTAQCVAERFSELEHLDRLS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         QGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLS

Mouse                         QGIQIVCETLTECWDHDPEARLTAQCVAERFSELEHPERLS

Rat                           QGIQIVCETLTECWDHDPEARLTAQCVAERFSELEHPDRLS

Chicken                       QGIQMVCETLIECWDHDPEARLTAQCVAERFSEFKHHDKLS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 23 – 567 TGF-beta receptor type-2
Topological domain 188 – 567 Cytoplasmic
Domain 244 – 544 Protein kinase
Region 439 – 567 Sufficient for interaction with CLU
Modified residue 548 – 548 Phosphoserine
Alternative sequence 81 – 567 Missing. In isoform 3.



Literature citations
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2.
Loeys B.L.; Chen J.; Neptune E.R.; Judge D.P.; Podowski M.; Holm T.; Meyers J.; Leitch C.C.; Katsanis N.; Sharifi N.; Xu F.L.; Myers L.A.; Spevak P.J.; Cameron D.E.; De Backer J.F.; Hellemans J.; Chen Y.; Davis E.C.; Webb C.L.; Kress W.; Coucke P.J.; Rifkin D.B.; De Paepe A.M.; Dietz H.C.;
Nat. Genet. 37:275-281(2005)
Cited for: VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528; The consensus coding sequences of human breast and colorectal cancers.
Sjoeblom T.; Jones S.; Wood L.D.; Parsons D.W.; Lin J.; Barber T.D.; Mandelker D.; Leary R.J.; Ptak J.; Silliman N.; Szabo S.; Buckhaults P.; Farrell C.; Meeh P.; Markowitz S.D.; Willis J.; Dawson D.; Willson J.K.V.; Gazdar A.F.; Hartigan J.; Wu L.; Liu C.; Parmigiani G.; Park B.H.; Bachman K.E.; Papadopoulos N.; Vogelstein B.; Kinzler K.W.; Velculescu V.E.;
Science 314:268-274(2006)
Cited for: VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.